Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing productsKey Takeaways:The survival benefits for a new gastric cancer drug, bemarituzumab, were weaker than expected in the final analysis of a Phase Three trialThe news unsettled investors, coming after Zai Lab's latest quarterly earnings also missed the markThe "Rule of 10" is a widely accepted yardstick within the biopharma industry for the chances of commercial succes ...